Seres Therapeutics
MCRB
77 hedge funds and large institutions have $258M invested in Seres Therapeutics in 2019 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 34 increasing their positions, 17 reducing their positions, and 22 closing their positions.
671% more call options, than puts
Call options by funds: $1.23M | Put options by funds: $160K
100% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 17
30% more capital invested
Capital invested by funds: $198M → $258M (+$60.1M)
0.06% more ownership
Funds ownership: 4.54% → 4.6% (+0.06%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
15% less funds holding
Funds holding: 91 → 77 (-14)
64% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAMA
Nikko Asset Management Americas
New York
|
+$9.31M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$9.31M |
| 3 |
BlackRock
New York
|
+$5.54M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$1.36M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$906K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$8.05M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.15M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$3.13M |
| 4 |
Goldman Sachs
New York
|
-$1.7M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$1.26M |
MCRB Hedge Fund Activity: Q3 2019 in Review
77 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q3 2019, worth a combined $258M — up 30% from $198M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of MCRB and 8 opened new positions — a net loss of 14 holders — while 17 trimmed existing stakes and 34 added.
The largest buyer was Nikko Asset Management Americas, adding an estimated $9.31M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $8.05M sold.
- 77 institutional investors held Seres Therapeutics (MCRB) as of Q3 2019, down from 91 in Q2 2019.
- Funds reported $258M of Seres Therapeutics stock for Q3 2019, up 30% quarter-over-quarter.
- 8 funds opened new Seres Therapeutics positions in Q3 2019 and 22 closed out, a net change of -14 holders.
- The largest Seres Therapeutics buyer in Q3 2019 was Nikko Asset Management Americas, an estimated $9.31M added.
- The largest Seres Therapeutics seller in Q3 2019 was Perceptive Advisors, an estimated $8.05M sold.
Based on aggregated 13F filings for Q3 2019.